

Surgery

Susmit

2022-06-21

Contents

Deep Vein Thrombosis (DVT)	2
Virchow's triad	2
Factors	2
Common sites	2
Prevention	2
CABG	2
Investigations for IHD	2
Indications for surgery	3
Graft selection	3
Types	3
Transfusion	3
Indications	3
Complications	3
Single transfusion	3
Massive transfusion	4
Blood & blood products	4
Clinical factoids	4
Burns	4
Mechanism of fluid loss	4
Assessment	4
Fluid resuscitation	5
Indications	5
Definitive management	5
Superficial partial-thickness burns	5
Deep partial-thickness/full-thickness burns	5
Nanocrystalline silver dressing	5

Deep Vein Thrombosis (DVT)

Formation of semisolid coagulum in a deep vein.

Virchow's triad

- Abnormal surface (endothelial damage)
- Abnormal flow (stasis / turbulence)
- Abnormal blood (thrombophilia)

Factors

- Immobility
 - Age
 - Obesity
 - Prolonged surgery
 - Pregnancy
 - Puerperium
 - Varicosity (effect of immobility, the rest are causes)
- Hormone-replacement therapy (high oestrogen)
- Previous DVT / PE
- Thrombophilia

Common sites

- Popliteal vein
- Femoral "
- Iliac "

Prevention

- Early mobilization
- Hydration
- Compression stockings
- Prophylactic LMW heparin
- Calf pumps
- Minimal use of tourniquets

CABG

Investigations for IHD

- ECG (first line)
- Cardiac enzymes (in acute coronary syndrome)

- Exercise tolerance test
- Echo: Evaluate
 - ventricular function
 - regional wall motion abnormalities
 - valvular lesions
- **Coronary angiography: gold std**
 - Extent, severity and location of stenoses
 - 70% reduction of diameter (i.e. >90% reduction of cross-sec) => severe

Indications for surgery

- 50% stenosis of the left coronary artery (“*left main stem*”)
- 50% stenosis of the proximal *LAD*
- 2/3 main coronary arteries diseased (*RCA*, *LAD*, *LCx*)

Graft selection

Types

- **Venous:** long saphenous vein
- **Arterial:**
 - LIMA most common (left internal mammary / left internal thoracic artery)
 - Others
 - * RIMA
 - * Radial
 - * Gastroepiploic
 - * Inf epigastric

Transfusion

Indications

- Acute blood loss
- Periop anaemia
- Symptomatic chronic anaemia

Complications

Single transfusion

- Haemolysis (haemolytic transfusion reaction)
- Fever (febrile transfusion reaction)
- Allergic reaction
- Infections
 - Hep B, C

- HIV
- Malaria
- Bacterial inf
- Air embolism
- Thrombophlebitis
- TRALI

Massive transfusion

- Coagulopathy
- Hypothermia
- Hypo-Ca
- Hypo-K
- Hyper-K

Blood & blood products

- Whole blood
- Components
 - Packed red cells
 - FFP
 - * Plasma stored at -40 to -50°C
 - * Rich in *coagulation factors*
 - * 2y shelf-life
 - Cryoprecipitate
 - * Supernatant of FFP
 - * Rich in *factor VIII* and *fibrinogen*
 - * Stored at -30°C
 - * 2y shelf-life
 - Platelet concentrate
 - Prothrombin complex concentrate

Clinical factoids

- Target Hb level: 10g/dL
- 1 unit transfusion = 1g/dL improvement

Burns

Mechanism of fluid loss

Intense inflammation in burnt areas → ↑ permeability → leakage of fluid into extravascular compartment

Assessment

- Rule of 9:
 - First approx

- Adult
 - * Head-neck → 9%
 - * Each upper limb → 9%
 - * Torso front 18%
 - * Torso back 18%
 - * Each lower limb 18%
 - * Perineum 1%
- Lund and Browder chart
 - More accurate
- For smaller burns, a piece of paper about the size of the hand to measure the burnt area directly. Size of hand \approx 1%.

Fluid resuscitation

Indications

- **If >10% TBSA in children or >15% TBSA in adults (B&L)**
- To correct hypovolaemia
- " " electrolyte imbalance
- To prevent shock
- To provide nutrition

Definitive management

Superficial partial-thickness burns

- Regular dressing
- Heal spontaneously within 2 wks without scar irrespective of choice of dressing

Deep partial-thickness/full-thickness burns

- Nanocrystalline silver dressing until surgery (to prevent colonisation)
- Escharotomy for circumferential full-thickness burns
- Debridement + split-skin grafting
- Without surgery, heal by hypertrophic scarring

Nanocrystalline silver dressing

- 1% silver sulfadiazine
- 0.5% silver nitrate
- Mafenide nitrate
- Silver sulfadiazine + cerium nitrate

Important anticancer drugs

- **Mitosis interferers**
 1. Vincristine

- 2. Vinblastine
- 3. Taxanes (e.g. Paclitaxel)
- **Antimetabolites** (i.e. DNA synthesis inhibitors)
 - 1. Methotrexate
 - 2. 5-FU
- **DNA damagers**
 - 1. Platinum drugs
 - Cisplatin
 - Carboplatin
 - Oxaloplatin
 - 2. Cyclophosphamide
 - 3. Bleomycin
 - 4. Doxorubicin
 - 5. Etoposide
- **Hormones**
 - 1. Tamoxifen: ER blocker (Breast ca)
 - 2. Goserelin: GnRH analogue; downregulate ant. pituitary \rightarrow \downarrow testosterone (Prostate ca)
 - 3. Flutamide: Androgen antagonist (Prostate ca)
 - 4. Bromocriptine: D2 agonist; blocks ant. pituitary stimul (Pituitary tumour)